BioCryst Pharmaceuticals Overview
- Year Founded
-
1986
- Status
-
Public
- Employees
-
435
- Stock Symbol
-
BCRX
- Investments
-
1
- Share Price
-
$7.22
- (As of Friday Closing)
BioCryst Pharmaceuticals General Information
Description
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Contact Information
Website
www.biocryst.comCorporate Office
- 4505 Emperor Boulevard
- Suite 200
- Durham, NC 27703
- United States
Corporate Office
- 4505 Emperor Boulevard
- Suite 200
- Durham, NC 27703
- United States
BioCryst Pharmaceuticals Timeline
BioCryst Pharmaceuticals Stock Performance
As of 20-Nov-2026, BioCryst Pharmaceuticals’s stock price is $7.22. Its current market cap is $1.86B with 257M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.22 | $7.30 | $6.23 - $11.22 | $1.86B | 257M | 4.94M | -$1.24 |
BioCryst Pharmaceuticals Financials Summary
As of 30-Sep-2026, BioCryst Pharmaceuticals has a trailing 12-month revenue of $962M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,568,871 | 2,076,315 | 2,036,762 | 1,674,647 |
| Revenue | 961,510 | 874,837 | 450,712 | 331,412 |
| EBITDA | (286,962) | 336,984 | (1,938) | (132,112) |
| Net Income | (359,656) | 263,861 | (88,881) | (226,539) |
| Total Assets | 591,070 | 514,158 | 490,420 | 516,960 |
| Total Debt | 784,454 | 438,874 | 808,742 | 825,148 |
BioCryst Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BioCryst Pharmaceuticals Comparisons
Industry
Financing
Details
BioCryst Pharmaceuticals Competitors (47)
One of BioCryst Pharmaceuticals’s 47 competitors is Sangamo Therapeutics, a Formerly VC-backed company based in Richmond, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Incyte | Formerly VC-backed | Wilmington, DE | ||||
| Spero Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Gilead | Formerly VC-backed | Foster City, CA |
BioCryst Pharmaceuticals Patents
BioCryst Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026217680-A1 | Inhibitors of complement protein c5 | Pending | 08-Apr-2025 | ||
| WO-2026174171-A1 | Inhibitors of complement protein c5 | Pending | 14-Feb-2025 | ||
| WO-2026174196-A1 | Tricyclic inhibitors of complement protein c5 | Pending | 14-Feb-2025 | ||
| WO-2026170177-A1 | Method of prophylaxis to prevent attacks of hereditary angioedema in pediatric patients | Pending | 10-Feb-2025 | ||
| WO-2026151989-A1 | Use of avoralstat in the treatment of diabetic macular edema and related ocular diseases | Pending | 12-Jan-2025 | A61K31/4418 |
BioCryst Pharmaceuticals Signals
BioCryst Pharmaceuticals Acquisitions (1)
BioCryst Pharmaceuticals’s most recent deal was a Merger/Acquisition with Astria Therapeutics for . The deal was made on 23-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Astria Therapeutics | 23-Jan-2026 | Merger/Acquisition | Drug Discovery |
BioCryst Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
30.27 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
BioCryst Pharmaceuticals FAQs
-
When was BioCryst Pharmaceuticals founded?
BioCryst Pharmaceuticals was founded in 1986.
-
Where is BioCryst Pharmaceuticals headquartered?
BioCryst Pharmaceuticals is headquartered in Durham, NC.
-
What is the size of BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals has 435 total employees.
-
What industry is BioCryst Pharmaceuticals in?
BioCryst Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is BioCryst Pharmaceuticals a private or public company?
BioCryst Pharmaceuticals is a Public company.
-
What is BioCryst Pharmaceuticals’s stock symbol?
The ticker symbol for BioCryst Pharmaceuticals is BCRX.
-
What is the current stock price of BioCryst Pharmaceuticals?
As of 20-Nov-2026 the stock price of BioCryst Pharmaceuticals is $7.22.
-
What is the current market cap of BioCryst Pharmaceuticals?
The current market capitalization of BioCryst Pharmaceuticals is $1.86B.
-
What is BioCryst Pharmaceuticals’s current revenue?
The trailing twelve month revenue for BioCryst Pharmaceuticals is $962M.
-
Who are BioCryst Pharmaceuticals’s competitors?
Sangamo Therapeutics, Incyte, Spero Therapeutics, Sorrento Therapeutics, and Gilead are some of the 47 competitors of BioCryst Pharmaceuticals.
-
What is BioCryst Pharmaceuticals’s annual earnings per share (EPS)?
BioCryst Pharmaceuticals’s EPS for 12 months was -$1.24.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process